A Controlled Trial of Losartan in Posttraumatic Stress Disorder

Summary

This study is being conducted to determine if losartan, an angiotensin receptor blocker (ARB), is safe and effective in the treatment of posttraumatic stress disorder (PTSD) symptoms. The study is also intended to determine if certain genetic markers are useful in predicting PTSD symptom reduction with losartan. Approximately 160 subjects with chronic PTSD ages 18-65 will participate in this study across five sites. Subjects will be assigned by chance to take either flexibly dosed losartan (up to a maximum dosage of 100 mg) or placebo (which resembles the study drug but has no active ingredients), once a day for 10 weeks. Furthermore, it is hypothesized that CC homozygotes for rs4311 SNP in the ACE gene will have a superior response to losartan on PTSD symptoms compared to T carriers.

Conditions

• Posttraumatic Stress Disorder

Interventions

DRUG

losartan

Angiotensin receptor blocker (ARB)

DRUG

Placebo

Placebo

Sponsors & Collaborators

• Mclean Hospital

  collaborator OTHER

• Massachusetts General Hospital

  collaborator OTHER

• Henry M. Jackson Foundation, Walter Reed National Military Medical Center

  collaborator UNKNOWN

• Foundation for Atlanta Veterans Education and Research, Inc.

  collaborator OTHER

• NYU Langone Health

  collaborator OTHER

• George Washington University

  collaborator OTHER

• University of California, San Diego

  lead OTHER

Principal Investigators

• Murray B Stein, MD, MPH · University of California, San Diego

• Kerry J Ressler, MD, PhD · McLean Hospital and Harvard Medical School

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-07-16

Primary Completion

2020-02-29

Completion

2020-09-29

Countries

• United States

Study Locations